A Phase II Trial of Panobinostat in Patients With Gastrointestinal Neuroendocrine Tumors.

Trial Profile

A Phase II Trial of Panobinostat in Patients With Gastrointestinal Neuroendocrine Tumors.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jun 2017 Status changed from completed to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top